Pay in 4 interest-free payments of $5.61 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Dai WL, et al
Our product pages are educational
Retrieved 29 January 2019
CagriSema's Advantages: First to Market: 6-12 month head start Leverages Wegovy Success: Built-in brand recognition Proven Semaglutide Component: Half the drug is already approved Strong Diabetes Data: Positions for dual indication No Dysesthesia: Cleaner safety profile in one key area Retatrutide's Advantages: Higher Efficacy: 28.7% vs 20.4% (8.3 points more) Superior BP Reduction: -14 mmHg vs likely similar to semaglutide Single Molecule: Potentially easier manufacturing Multiple Indications: OA, OSA, obesity, diabetes trials Novel Class: First triple agonist = strong IP protection The Verdict: Market Will Support Both These medications won't compete head-to-head
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al
US$ 26.09
US$ 25.51
US$ 20.97
US$ 23.97
US$ 26.79
US$ 27.95
US$ 21.91
US$ 28.72
:max_bytes(150000):strip_icc()/VWH-GettyImages-2170138295-1e664f5616224ea39b5ba836a469d10b.jpg)
